Market Data 
Markets
Explore small cap ideas before they hit the headlines.
Interestingly, within the past two weeks at least five directors have set up rule 10b5-1 trading plans.
Why is that interesting? Besides everyone doing it more or less at the same time, this trading plan establishes a clear defense against any allegations of insider trading.
Why would these people feel that such a thing might be of concern? They're expecting some significant incoming gains from stock holdings...and they wish to protect those gains.
Sounds reasonable. Invest wisely.
THV
Bearish Signal Reversed since 6 Jan 2026. GLTA
Nice analyst upgrade $10-$11
4.99 ...https://www.globenewswire.com/news-release/2025/12/08/3201434/0/en/index.html· 7m23minsRecursion Pharmaceuticals(RXRX.US)4.7104.939-4.27%+4.86%
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).Through an unbiased phenotypic screen of thousands of compounds, the earliest version of the Recursion OS identified selective MEK1/2 inhibition as a highly specific mechanism capable of reversing APC loss-of-function signatures. Using high-content cellular phenomics driven by AI, REC-4881 emerged as one of the strongest phenotypic rescue hits, reverting APC-deficient cells toward a healthy state and suppressing ERK/MAPK hyperactivation downstream of APC loss. Guided by this AI-driven insight, Recursion and redirected REC-4881—originally evaluated clinically in solid tumors—as a mechanistically aligned therapeutic candidate for FAP. REC-4881 is now the first MEK1/2 inhibitor ever studied clinically for this disease."The durable polyp burden reduction demonstrated by REC-4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community," said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study. "Given the near-100% lifetime risk of colorectal cancer and the absence of any approved medical therapies, patients today often face a lifetime of intensive surveillance and life-altering surgeries. These Phase 2 results provide a meaningful basis for hope and support the potential for REC-4881 to offer a much-needed non-surgical option for this debilitating, life-long disease.""These Phase 2 results mark a meaningful validation of the Recursion OS," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. "An unbiased phenotypic insight from our platform and driven by AI—linking MEK1/2 inhibition to APC loss-of-function biology—has now translated into rapid, substantial, and durable reductions in polyp burden in patients. This is a powerful example of how even the earliest versions of the Recursion OS can uncover therapeutic opportunities in diseases with no approved pharmacotherapy options. And since this discovery, we've only added to the breadth, depth, and power of the Recursion OS; we believe this is the first of many potential medicines that will advance as our flywheel of discovery accelerates."In the Phase 2 portion of the study, REC-4881 demonstrated rapid and durable reductions in polyp burden, with 43% median reduction in evaluable patients after 12 weeks of treatment. 75% of evaluable patients had a reduction in polyp burden in this same period. Importantly, the effect persisted well beyond the dosing period: 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therapy—with a 53% median decrease from baseline. These results are especially meaningful when considered alongside real-world natural history analyses showing that untreated FAP patients are expected to experience increases when left untreated."This program reflects a full validation cycle of the Recursion OS: an unbiased phenotypic signal identifying MEK1/2 inhibition as a rescue mechanism for APC loss-of-function, followed by mechanistic confirmation, clinical translation, and now encouraging human data in a disease with no approved medical therapies," said Najat Khan, Ph.D., Chief R&D and Commercial Officer and incoming President and CEO. "REC-4881, an allosteric MEK1/2 inhibitor, represents a first precision-medicine approach for the causal biology of FAP. In TUPELO, we are seeing rapid, substantial, and durable reductions in polyp burden — including sustained benefit after patients stop therapy. Equally important, our ClinTech and real-world data capabilities have been instrumental in guiding this program — from refining eligibility to contextualizing a single-arm dataset with a first-of-its-kind natural history study."About FAP
Next week, it will likely push through $7 again. Trouble is, swing it or hold for gold since their physical trial data could likely being positive will push it double digits.The earnings report we may see revenues increase again, while net earnings will likely be negative. If they beat Q2's net earnings per share $-0.42, that would look positive. Good luck with $RXRX👍 Its wild horse
In Double Top Breakout mode since Oct-1-2025. GLTA
RXRX should benefit of latest executive order UNLOCKING CURES FOR PEDIATRIC CANCER WITH ARTIFICIAL INTELLIGENCE
https://www.whitehouse.gov/presidential-actions/2025/09/unlocking-cures-for-pediatric-cancer-with-artificial-intelligence/
Yes! Exciting one to be in. Cathie Woods w/ ARK Investment owns 20% of$RXRX at $6 range. NVDA has a nice stake in it too. At these pps levels, i am bullish
Double Top Breakout on 18-Sep-2025. GLTA
|
Followers
|
35
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
210
|
|
Created
|
12/07/21
|
Type
|
Free
|
| Moderators | |||
U.S. stock futures pointed to a modestly positive start on Monday, with investors encouraged by reports of progress in diplomatic negotiations between the United States and Iran and by a continued decline in oil prices. The positive tone follows strong gains recorded during the previous trading session, although investors remain cautious as they await further […]
